Evidence map›Paper›PMID 35242522›Full record

ArticleRespiratory medicine case reports2022

A case of squamous cell lung cancer treated with anamorelin in combination with a multidisciplinary collaborative approach for treating cancer cachexia.

Yuri Oshima, Hiroyuki Matsuura, Yusuke Sakurai, Kaho Hirai, Eriko Tani, Naoki Yoshimoto, Kenichi Minami, Fumio Yamasaki, Mayu Nishime, Tomonori Hirashima

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yuri OshimaDepartment of Respiratory Medicine, Ishikiriseiki Hospital, Osaka, Japan.
Hiroyuki MatsuuraDepartment of Respiratory Medicine, Ishikiriseiki Hospital, Osaka, Japan.
Yusuke SakuraiDepartment of Respiratory Medicine, Ishikiriseiki Hospital, Osaka, Japan.
Kaho HiraiDepartment of Respiratory Medicine, Ishikiriseiki Hospital, Osaka, Japan.
Eriko TaniDepartment of Respiratory Medicine, Ishikiriseiki Hospital, Osaka, Japan.
Naoki YoshimotoDepartment of Respiratory Medicine, Ishikiriseiki Hospital, Osaka, Japan.
Kenichi MinamiDepartment of Respiratory Medicine, Ishikiriseiki Hospital, Osaka, Japan.
Fumio YamasakiDivision of Rehabilitation, Ishikiriseiki Hospital, Osaka, Japan.
Mayu NishimeDivision of Nutrition Management, Ishikiriseiki Hospital, Osaka, Japan.
Tomonori HirashimaDepartment of Thoracic Oncology, Ishikiriseiki Hospital, Osaka, Japan.
Ishikiriseiki Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anamorelin (ANA) is approved for treating cancer cachexia (CCX) in Japan. We report the case of a 69-year-old man with stage IVB squamous cell lung cancer complicated by CCX, having a 13.6% weight loss in 6 months. After chemotherapy was initiated, his weight was further reduced. Therefore, we started ANA combined with a treatment approach by a multidisciplinary collaboration, including nutritionists and physical therapists. After initiation of ANA, the body weight, appetite, psoas muscle index, and physical functions rapidly improved during chemotherapy. ANA administration combined with a multidisciplinary collaboration approach can be an effective supportive therapy against CCX during chemotherapy.

Indexed as

ANA, anamorelinAnamorelinBMI, body mass indexBW, body weightBWL, body weight lossCancer cachexiaCCX, cancer cachexiaCT, computed tomographyLBM, lean body massLung cancerMultidisciplinary collaborationNSCLC, non-small cell lung cancerPMI, psoas muscle index

Identifiers

PMID35242522
PMCPMC8866093
OpenAlexW4225852055

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.